HLA-A*0201 & B2M & hTERT (ILAKFLHWL)

HLA-A*0201 & B2M & hTERT (ILAKFLHWL) Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Human (3)
Etikett
His Tag (2)His Tag & Avi Tag (1)
Marker
APC Labeled (1)PE Labeled (1)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HLT-H82E5	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&hTERT (ILAKFLHWL) Complex Protein (Monomer, MALS verified)	In den Warenkorb legen
HLT-HA2H7	Human	HEK293	APC-Labeled Human HLA-A*02:01&B2M&hTERT (ILAKFLHWL) Tetramer Protein	In den Warenkorb legen
HLT-HP2H5	Human	HEK293	PE-Labeled Human HLA-A*02:01&B2M&hTERT (ILAKFLHWL) Tetramer Protein	In den Warenkorb legen

Gesamtmenge3

HLA-A*0201 & B2M & hTERT (ILAKFLHWL) Molekülhintergrund

hTERT (human Telomerase Reverse Transcriptase), the catalytic subunit of telomerase, maintains telomere length to drive tumor cells’ unlimited proliferation. It is highly expressed in ~85-90% of cancers but silenced in most normal somatic cells. The peptide ILAKFLHWL (from hTERT residues 540-548) acts as a tumor-specific antigen. It binds to MHC class I molecule HLA-A0201 to form a surface complex on tumors, activating cytotoxic T lymphocytes (CTLs). The Human HLA-A*0201 hTERT (ILAKFLHWL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and ILAKFLHWL peptide of the hTERT.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
JWATM-203	JWATM-203; JWATM203	Phase 2 Clinical	Suzhou Yaomingjunuo Biotechnology Co Ltd	Carcinoma, Hepatocellular	Details
SynOV1.1		Phase 2 Clinical	Beijing Syngentech Co Ltd	Solid tumours; Carcinoma, Hepatocellular	Details
ET140203		Phase 2 Clinical	Eureka Therapeutics Inc	Liver Neoplasms; Hepatoblastoma; Carcinoma, Hepatocellular	Details
Alpha fetoprotein targeted T-cell therapy (Adaptimmune)	AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T	Phase 1 Clinical	Adaptimmune Llc	Liver Neoplasms	Details
HRYZ-T102	HRYZ-T102	Phase 1 Clinical	Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd	Solid tumours; Carcinoma, Hepatocellular	Details
ET1402L1-CART	AFP/ET-1402; ET1402; ET-1402; AFP-CAR; ET-140202	Phase 1 Clinical	Eureka Therapeutics Inc	Liver Neoplasms; Carcinoma, Hepatocellular	Details
TAEST-1901	TAEST-1901	Phase 1 Clinical	Xiangxue Life Science Technology (Guangdong) Co Ltd	Liver Neoplasms; Neoplasms	Details
ET1402L1-ARTEMIS T cells		Phase 1 Clinical	Aeon Therapeutics (Beijing) Co Ltd	Liver Neoplasms; Carcinoma, Hepatocellular	Details
CPU-118	CPU-118	Phase 1 Clinical	China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd	Liver Neoplasms; Solid tumours; Neoplasms	Details